Significant’ findings suggest potential for effective, non-toxic treatment for this aggressive childhood cancer
Dublin, Ireland: Researchers investigating new treatments for neuroblastoma – one of the most common childhood cancers – have found that a combination of two drugs made tumours disappear in mice, making it more effective than any other drugs tested in these animals.
Professor Murray Norris, deputy director of the Children’s Cancer Institute Australia for Medical Research, Sydney, Australia, told the 30th EORTC-NCI-AACR  Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today (Thursday) that the findings were unusual and highly significant. But he warned that it would be some time before the drug combination would be tested in children and, if successful, made available more widely to treat children with this disease, even though both drugs are currently undergoing clinical trial in a range of adult cancers.
Neuroblastoma is one of the most common childhood cancers and is the leading single cause of cancer deaths in children under five. It is frequently found in the adrenal glands on top of the kidneys. Despite using intensive treatment regimens, children with the most aggressive forms of neuroblastoma have less than 50% survival rates.
Prof Norris said: “To study neuroblastoma in the laboratory, we use a genetically modified neuroblastoma mouse model that closely recapitulates clinical features of the disease, and these mice spontaneously develop neuroblastomas within weeks after birth. We have found that when we combined CBL0137 and panobinostat to treat mice bearing neuroblastomas, the tumours disappeared and never came back during the entire experiment, whereas the tumours continued to grow in mice that received either no treatment or only single drug treatment.
“This is a highly significant finding as this drug combination is the most effective therapy that we have observed in this neuroblastoma mouse model. It is unusual to see this effect, especially in these mice where neuroblastoma develops within seven weeks of birth and is aggressive in nature. In fact, the CBL0137/panobinostat combination is more effective than any other current clinical chemotherapy combinations that our laboratory has tested in these mice.”
CBL0137, which belongs to a new class of drugs called curaxins, attacks the structure of cancer cells but is a safe drug that does not damage DNA in normal cells. Prof Norris and his colleagues used RNA sequencing technology that can detect drug-induced changes in tumours, to see how the combination of CBL0137 and panobinostat stopped neuroblastoma growing.
“Our results suggest that these drugs work through two different mechanisms that offer a two-pronged attack. One of these mechanisms appears to be a direct attack on the cancer cells themselves, killing them by inhibiting DNA repair; then a second mechanism is involved in inducing a robust immune response. This is very exciting and will hopefully facilitate the clinical development of effective and non-toxic therapies for childhood cancer,” he said.
“Unlike conventional chemotherapy drugs that interact with DNA, CBL0137 is non-DNA damaging and therefore is comparatively less toxic. Developing CBL0137 combination therapies has the potential to reduce acute and long-term side effects and increase the quality of life of children with cancer while extending the survival rates of these children. Another important implication is that the CBL0137/panobinostat combination can activate an immune response which may significantly boost the efficacy of immunotherapy drugs that are otherwise ineffective for neuroblastoma.”
The researchers are continuing their laboratory work to investigate further how the combination of these two drugs activates the immune response, and to test CBL0137/panobinostat with other immunotherapy drugs in mice. A phase I clinical trial of CBL0137 in children with neuroblastoma and other difficult-to-treat childhood cancers is planned to start in 2019, following the completion of a phase I clinical trial of the drug in adults with solid cancers and previously treated blood cancers. The trial of CBL0137 alone in children will need to be completed successfully before a trial testing the combination of the two drugs can be planned, which means it will be a few years before it is known whether the treatment can be used more widely.
Further lab research by Prof Norris and his colleagues also showed that CBL0137 and panobinostat slowed the growth of aggressive childhood leukaemias in mice and significantly extended survival.
In addition to approving CBL0137 for phase I clinical trials in adults, the FDA has already approved panobinostat for multiple myeloma and it is being tested in clinical trials for a range of other cancers.
The Latest on: Neuroblastoma
via Google News
The Latest on: Neuroblastoma
- 2 Year Old Florida Girl Needs Rare Blood Donors to Survive on December 17, 2018 at 11:44 am
New Jersey Blood Services (NJBS) is assisting in an international search to find blood donors who match a 2 year-old Florida girl recently diagnosed with neuroblastoma, an aggressive form of ... […]
- Huntsville Joins Worldwide Search for Rare Blood Donors to Save Toddler on December 16, 2018 at 9:01 pm
HUNTSVILLE Ala. - Two-year-old Zainab Mughal has neuroblastoma, an aggressive cancer. Doctors say fighting it would require two bone marrow transplants and a series of blood transfusions. […]
- Fundraiser launched to get Ed Sheeran-obsessed Maya Nash, 5, from Etchinghill near Folkestone to US for neuroblastoma cancer treatment on December 16, 2018 at 4:04 pm
An appeal for almost £250,000 has been launched to help get a five-year-old Ed Sheeran fan to America for a new cancer treatment not available in the UK. Maya Nash's parents thought their little girl ... […]
- Blake Shelton Thanks Hospital for Treating His Cousin by Establishing Cancer Research Program on December 14, 2018 at 1:31 am
The country music star credits the Oklahoma University's Children's Hospital for his neuroblastoma tumor-stricken cousin's survival. AceShowbiz - Blake Shelton demonstrates his support towards cancer ... […]
- Children's Hospital of Philadelphia Announces Endowed Chair in Pediatric Neuroblastoma Research on December 13, 2018 at 3:07 pm
--CHOP Recipient, Physician-Scientist Dr. Yael Mossé, Is Innovating Targeted, Less Toxic Therapies for Cancer Affecting Mostly Infants and Young Children-- Newswise — Philadelphia, Dec. 13, 2018--Pedi... […]
- Blake Shelton Establishes Cancer Research Program at Children's Hospital in Honor of His Cousin on December 13, 2018 at 10:25 am
Neuroblastoma is a type of cancer that forms in the nerve tissue, and it is the most common cancer found in infants. According to the Children’s Hospital Foundation, Van Horn had to endure two ... […]
- How her toddler's experience led this British expat to focus on eradicating pediatric cancer on December 12, 2018 at 1:16 pm
Melissa Wiggins had to lead her son, Cannon, through his treatment for stage 4 neuroblastoma cancer when he was still a toddler — and she experienced the horrific effects first hand. After that, she s... […]
- Mechanisms of Neuroblastoma Growth and Regression Deciphered on December 11, 2018 at 1:47 pm
The genetic factors behind different neuroblastoma subtypes and their prognoses have been studied by researchers from Charité - Universitätsmediz in Berlin. Peripheral nervous system tumors are one of ... […]
- Europe Neuroblastoma Market and Competitive Landscape - 2018 - ResearchAndMarkets.com on December 11, 2018 at 2:37 am
The "Europe Neuroblastoma Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. Europe Neuroblastoma Market and Competitive Landscape - 2018, provides co... […]
via Bing News